Physician profile
Kai He
NPI 1114245420
$49,085.21
in general payments reported to CMS, 2019-2025
22 companies · $25K in 2025
The $25K reported for 2025 was more than what 90% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,118 · 2020: $83.99 · 2021: $1,574 · 2022: $2,398 · 2023: $7,698 · 2024: $10K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $3,823 · Food and Beverage: $2,034 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,615.41 |
| Travel and Lodging | $3,822.72 |
| Food and Beverage | $2,033.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34,241.15 | 2019-2025 | Opdivo |
| Biontech Se | $3,720.96 | 2023-2024 | |
| Amgen INC. | $2,744.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $2,397.50 | 2022 | |
| F. Hoffmann-La Roche Ag | $1,907.48 | 2019 | |
| Pfizer INC. | $1,555.59 | 2024 | |
| Janssen Biotech, INC. | $1,484.05 | 2025 | Rybrevant |
| Genentech USA, INC. | $226.80 | 2024-2025 | Tecentriq, Alecensa |
| Galvanize Therapeutics, INC | $161.12 | 2025 | Aliya System |
| Genentech, INC. | $144.10 | 2019-2020 | |
| Beigene USA, INC. | $129.26 | 2023 | Brukinsa |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $75.29 | 2025 | |
| Novartis Pharmaceuticals Corporation | $74.18 | 2021 | |
| Janssen Scientific Affairs, LLC | $67.46 | 2025 | Rybrevant |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Bioinnovation | $47.33 | 2025 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.